Recent news from a professional soccer team in Bolivia has surprised the pharmaceutical community. Spain’s El Mundo reported in March of 2015 that the River Plate soccer team, hailing from Argentina, touted the use of Sildenafil to combat altitude sickness. Sildenafil Citrate, the erectile dysfunction therapy known also as Viagra, is certainly a unique remedy[…]
Sildenafil to Combat Altitude Sickness – Can it Work?
Cardiovascular Agent, Drug Research & Development API Tags: erectile dysfunctionpulmonary arterial hypertension Oct 09, 2015
Ezetimibe and Simvastatin Shine In Recent Study Results
Cardiovascular Agent, Drug Research & Development API, OTC and Compounding Product Tags: EzetimibeLDLSimvastatin Apr 28, 2015
The culmination of a six year study led by cardiologists at Duke University showcased the phenomenal benefits of cholesterol lowering agents Ezetimibe and Simvastatin, also known as the brand name drug Vytorin. Study results were conclusive in determining the importance of low LDL levels of cholesterol, with ultra-low levels being ideal. Not only does lowering[…]
Tadalafil Tested as Possible Dementia Therapy
Blood Product, Cardiovascular Agent, Drug Research & Development API, OTC and Compounding Product Tags: erectile dysfunctionUnited States Mar 16, 2015
The close of 2014 brought exciting news for patients suffering from dementia with the announcement that Tadalafil, a commonly used drug that treats erectile dysfunction, is being tested as a treatment for dementia. The Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Society UK shared the news of their partnership and funding, which would be earmarked[…]
ED Medication for Duchenne Muscular Dystrophy Shows Encouraging Results
Cardiovascular Agent, Drug Research & Development API, OTC and Compounding Product Tags: Duchenne Muscular Dystrophy May 19, 2014
As a debilitating disease which destroys the muscles Duchenne Muscular Dystrophy, also known as DMD is a genetic disorder. DMD affects mainly males, and it is characterized by extreme muscle fatigue and excessive muscle degeneration. The cause of Duchenne Muscular Dystrophy is a lack of dystrophin in the body, which is the necessary protein that[…]
FDA Approves Pivotal Cardiovascular Drug Vorapaxar
Antithrombotic, Cardiovascular Agent, Drug Research & Development API, FDA Approved 2014 Tags: Drug Administration May 15, 2014
On May 8, 2014 the U.S. Food and Drug Administration approved the formidable cardiovascular drug Vorapaxar. Known as the brand name Zontivity, which is marketed by Merck, this pivotal medication has proven to be outstanding in clinical trials. In three short years of study Vorapaxar demonstrated its ability to successfully reduce the rate of death[…]
Fast Track Designation for Chronic Heart Failure Drug Ivabradine
Cardiovascular Agent, Drug Research & Development API Tags: chronic heart failureWorld Health Organization May 05, 2014
Ivabradine, also known as the brand name drug Procorlan which is marketed by Servier, recently received a fast track from the FDA for the treatment of chronic heart failure. As an efficacious drug which inhibits the IF current in the sinoatrial node, Ivabradine has proven to be a virtuous symptomatic treatment for chronic stable angina[…]
Serelaxin Works for the Treatment of Acute Heart Failure
Cardiovascular Agent, FDA Breakthrough Therapy Status Tags: heart failure Oct 25, 2013
Positive studies of the recombinant human relaxin-2, known as Serelaxin, have continued to emerge, offering excitement in the pharmaceutical arena. On October 25, 2013 study data published on Medscape via The Lancet revealed the most recent data from a randomized and placebo controlled trial. This trial, coined RELAX-AHF, aimed to test the hypothesis that patients[…]
FDA Approves Macitentan for Pulmonary Arterial Hypertension
Cardiovascular Agent, Drug Research & Development API Tags: PAHpulmonary arterial hypertension Oct 24, 2013
On October 19, 2013 the FDA approved Macitentan for the treatment of pulmonary arterial hypertension, also known as PAH. As the first oral drug approved as a potential reduction for patient hospitalizations, Macitentan is also being touted to delay disease progression in patients with PAH. Actelion markets the brand name of Macitentan, coined Opsumit, is[…]
Breaking News: Riociguat FDA Approval Brings Relief
Cardiovascular Agent, Drug Research & Development API Tags: Europehypertension Oct 10, 2013
Riociguat, CAS# 625115-55-1, was approved yesterday by the FDA for the treatment of thromboembolic pulmonary hypertension. Known as the brand name Adempas, Riociguat has proven in trials to be an efficacious treatment option for adults with both persistent and recurrent thromboembolic pulmonary hypertension. The patient population suffering from chronic (CTPH) or recurrent thromboembolic pulmonary hypertension is[…]
Rare Breakthrough Therapy Designation for Amifampridine Phosphate
Cardiovascular Agent, Drug Research & Development API, FDA Approved 2010, FDA Breakthrough Therapy Status Tags: acetylcholine Sep 09, 2013
Patients suffering from the rare neuromuscular disorder Lambert-Eaton myasthenic syndrome have recently received life changing news. On August 27, 2013 the FDA decided to grant Amifampridine Phosphate a Breakthrough Therapy Designation, also known as BTD. Marketed by BioMarin as the brand name Firdapse, Amifampridine Phosphate offers a crucial new hope for patients enduring this fatal[…]
